Who has been buying Enzychem Life Science stock?

4 distinct insiders have filed 10 disclosed insider purchases in Enzychem Life Science (183490), most recently on 2026-03-31. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Enzychem Life Science have?

Enzychem Life Science has 10 buy-side and 4 sell-side disclosures on record, covering ₩67M ($47K) in total reported value, spanning 2024-02-14 to 2026-03-31.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Enzychem Life Science 183490

Company

엔지켐생명과학Enzychem Life Science

Insiders

Buys

Total Value

₩67M ($47K)

Avg Return

-11.07%

Last Filing

2026-03-31

Enzychem Life Science (183490) has 10 disclosed insider purchases and 4 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩67M ($47K) in reported transaction value. The earliest filing StockDrifts holds for Enzychem Life Science is dated 2024-02-14; the most recent is 2026-03-31. Across these filings the average return since disclosure is -11.07%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-23	BUY	신규선임	김진원 Jinwon Kim	Internal director	55.0K	₩990	+0.0%	₩54M ($38K)
2026-03-31	BUY	신규선임	구병주 Koo Byeong-ju	Outside Director	7.2K	₩990	+0.0%	₩7M ($5K)
2024-08-23	SELL	Market Sell	윤영배 Youngbae Yoon	vice president	-1	₩1,602	+14.5%	₩2K ($1)
2024-08-23	SELL	Market Sell	윤영배 Youngbae Yoon	vice president	-5.0K	₩1,602	+14.5%	₩8M ($6K)
2024-08-23	BUY	Market Buy	윤영배 Youngbae Yoon	vice president	8.0K	₩1,602	-14.5%	₩13M ($9K)
2024-08-23	SELL	Market Sell	윤영배 Youngbae Yoon	vice president	-1	₩1,602	+14.5%	₩2K ($1)
2024-08-23	SELL	Market Sell	윤영배 Youngbae Yoon	vice president	-3.0K	₩1,602	+14.5%	₩5M ($3K)
2024-06-11	BUY	Market Buy	윤영배 Youngbae Yoon	vice president	1.6K	₩1,897	-27.8%	₩3M ($2K)
2024-05-30	BUY	Market Buy	윤영배 Youngbae Yoon	vice president	2.0K	₩1,965	-30.3%	₩4M ($3K)
2024-04-18	BUY	Market Buy	윤영배 Youngbae Yoon	vice president	1.7K	₩1,760	-22.2%	₩3M ($2K)
2024-03-29	BUY	Market Buy	최재호 Jaeho Choi	Managing Director	4.7K	₩1,883	-27.2%	₩9M ($6K)
2024-03-06	BUY	Market Buy	윤영배 Youngbae Yoon	vice president	2.5K	₩1,600	-14.4%	₩4M ($3K)
2024-02-26	BUY	Market Buy	정재한 Jaehan Jeong	Managing Director	6.2K	₩1,651	-17.0%	₩10M ($7K)
2024-02-22	BUY	Market Buy	김동성 Kim Dong-seong	vice president	500	₩1,663	-17.6%	₩832K ($577)
2024-02-20	BUY	Market Buy	김동성 Kim Dong-seong	vice president	3.8K	₩1,718	-20.3%	₩7M ($5K)
2024-02-14	BUY	Market Buy	최재호 Jaeho Choi	Managing Director	570	₩1,750	-21.7%	₩998K ($693)

Frequently asked questions

Who has been buying Enzychem Life Science stock?: 4 distinct insiders have filed 10 disclosed insider purchases in Enzychem Life Science (183490), most recently on 2026-03-31. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Enzychem Life Science have?: Enzychem Life Science has 10 buy-side and 4 sell-side disclosures on record, covering ₩67M ($47K) in total reported value, spanning 2024-02-14 to 2026-03-31.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.